Kasper is a biochemist and molecular biologist (PhD, Health Sciences) with deep experience in preclinical drug discovery and platform validation. He builds cellular models and assays to generate proof-of-concept data and clarify mechanism-of-action. His research has centered on RNA and RNA–protein complexes as targets and therapeutic modalities, and he has also contributed to small-molecule programs across oncology, infectious disease, and metabolic indications.

Before co-founding Biohagen Labs, Kasper served as an Assistant Professor at BRIC (University of Copenhagen), where he established screening and validation pipelines for small molecules targeting ribosome function and RNA modifications, combining biochemical assays with proteomics and RNA-seq. He later joined Novo Holdings SeedLab as a Senior Scientist, supporting identification and experimental evaluation of early-stage biotech assets and translating novel science into decision-ready datasets for startups, pharma/biotech partners, and investors. With international research experience across six countries, including UC Berkeley, and a strong publication and funding track record, Kasper brings scientific rigor, broad technical range, and clear communication to high-stakes validation work.